keyword
MENU ▼
Read by QxMD icon Read
search

Graves' orbitopathy

keyword
https://www.readbyqxmd.com/read/29332250/the-levels-of-12-cytokines-and-growth-factors-in-tears-hyperthyreosis-vs-euthyreosis
#1
Jelena Juri Mandić, Ana Kozmar, Sanja Kusačić-Kuna, Anamarija Jazbec, Krešimir Mandić, Danijela Mrazovac, Nenad Vukojević
PURPOSE: Simultaneous analyses of the contents and ratios of 12 cytokines and growth factors in single samples of human tears were performed, and the results were compared between a group of healthy subjects and a group of patients with Graves' hyperthyreosis (GH) without thyroid-associated orbitopathy (TAO). METHODS: Determinations and concentration measurements of interleukins (IL-2, IL4, IL-6, IL-8, IL-10, IL-1α, and IL-1β) interferon (IFN-γ), tumor necrosis factor (TNF-α), monocyte chemoattractant protein (MCP-1), vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF) were performed with single tear samples from 21 patients with hyperthyreosis and 22 healthy subjects...
January 14, 2018: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29329570/exophthalmos-in-a-young-woman-with-no-graves-disease-a-case-report-of-igg4-related-orbitopathy
#2
Annamaria Erdei, Zita Steiber, Csaba Molnar, Ervin Berenyi, Endre V Nagy
BACKGROUND: Immunoglobulin G4-related disease (IgG4-rd) is characterized by lymphoplasmacytic infiltration and tissue fibrosis. Orbital manifestations of IgG4-rd may include unilateral or bilateral proptosis, cicatricial extraocular muscle myopathy, orbital inflammation and pain which may mimic ophthalmic Graves' disease. CASE PRESENTATION: A 25-year-old woman has been referred to the endocrinology clinic, 4 months after delivery, with suspected Graves' orbitopathy...
January 12, 2018: BMC Ophthalmology
https://www.readbyqxmd.com/read/29319381/novel-use-of-non-echo-planar-diffusion-weighted-mri-in-monitoring-disease-activity-and-treatment-response-in-active-grave-s-orbitopathy-an-initial-observational-cohort-study
#3
Ravi Kumar Lingam, Pravin Mundada, Vickie Lee
AIM: To examine the novel use of non-echo-planar diffusion weighted MRI (DWI) in depicting activity and treatment response in active Grave's orbitopathy (GO) by assessing, with inter-observer agreement, for a correlation between its apparent diffusion coefficients (ADCs) and conventional Short tau Inversion Recovery (STIR) MRI signal-intensity ratios (SIRs). METHOD AND MATERIALS: A total of 23 actively inflamed muscles and 30 muscle response episodes were analysed in patients with active GO who underwent medical treatment...
January 10, 2018: Orbit
https://www.readbyqxmd.com/read/29319139/the-role-of-99mtc-dtpa-retrobulbar-spect-in-staging-and-follow-up-of-graves-orbitopathy
#4
László Galuska, Sándor Barna, József Varga, Ildikó Garai, Endre V Nagy
The pathogenesis of Graves' orbitopathy (GO) is not completely understood. Coexistent hyperfunction of the thyroid gland is frequent; however, GO may also coexist with hypo- or euthyrodism. The course of GO is largely independent of thyroid function, although elevated serum TSH is known to negatively interfere with GO course. GO is severe in 10 % of the cases; sight threatening complications may also develop. A successful therapy of GO requires the assesment of both the severity and activity of orbital inflammation...
January 10, 2018: Nuclear Medicine Review. Central & Eastern Europe
https://www.readbyqxmd.com/read/29260102/tocilizumab-as-a-steroid-sparing-agent-for-the-treatment-of-graves-orbitopathy
#5
David J Russell, Lilly H Wagner, Stuart R Seiff
Purpose: To describe the effect of tocilizumab in two patients with thyroid associated orbitopathy (TAO). Observations: We present two patients with TAO who could not tolerate corticosteroids and had a reduction in clinical and laboratory markers of inflammatory activity with subsequent tocilizumab therapy. Conclusions and importance: The IL-6 receptor antibody tocilizumab is a promising candidate for the treatment of TAO because it selectively targets a key inflammatory mediator and has a favorable side effect profile...
September 2017: American Journal of Ophthalmology Case Reports
https://www.readbyqxmd.com/read/29234854/commentary-for-the-article-a-comparative-study-of-full-thickness-blepharotomy-versus-transconjunctival-eyelid-lengthening-in-the-correction-of-upper-eyelid-retraction-in-graves-orbitopathy
#6
https://www.readbyqxmd.com/read/29198022/hyperthyroid-patients-without-graves-orbitopathy-are-not-at-increased-risk-of-developing-glaucoma-a-nationwide-danish-register-based-case-control-study
#7
F Brandt, M Thvilum, L Hegedüs, T H Brix
PURPOSE: Graves' disease (GD) and toxic nodular goiter (TNG) are associated with various comorbidities. However, it is unclarified whether TNG and GD without orbitopathy are associated with glaucoma. METHODS: This was a case-control study using record-linkage data from nationwide Danish health registers. 28,461 patients with GD and 17,283 with TNG were included. Each case was age and sex matched with four non-hyperthyroid controls and followed over a mean period of 8 years...
December 2, 2017: Endocrine
https://www.readbyqxmd.com/read/29190000/a-genome-wide-dna-methylation-analysis-in-peripheral-blood-from-patients-identifies-risk-loci-associated-with-graves-orbitopathy
#8
Z Xin, L Hua, T-T Shi, X Tuo, F-Y Yang, Y Li, X Cao, J-K Yang
OBJECTIVE: Graves' orbitopathy (GO) is an inflammatory orbital disease of autoimmune origin with the potential to cause severe functional and psychosocial effects. The pathogenesis has not been fully elucidated. We investigated whether DNA methylation was associated with GO incidence in Chinese patients. MATERIALS AND METHODS: Six GO patients and six age-matched controls were recruited, and genome-wide DNA methylation patterns were analyzed in their peripheral blood...
November 30, 2017: Journal of Endocrinological Investigation
https://www.readbyqxmd.com/read/29187926/-management-of-moderate-and-severe-dysthyroid-orbitopathy-about-22-cases
#9
Nadia Daldoul, Leila Knani, Faten Gatfaoui, Hechmi Mahjoub
Our study aimed to describe the therapeutic management of moderate and severe dysthyroid orbitopathies and to evaluate the factors associated with optic neuropathy as well as the prognostic factors of poor visual outcome using a statistical analysis. We conducted a retrospective study of 22 patients presenting with moderate to severe dysthyroid orbitopathy in at least one eye and hospitalized in the Department of Ophthalmology at the University Hospital Farhat Hached, Sousse over the period from 1998 to 2015...
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/29151039/pretibial-myxoedema-without-thyroid-associated-orbitopathy-in-a-patient-with-graves-disease
#10
Sailesh Lodha, Nimisha Jain, Anil Bhansali
No abstract text is available yet for this article.
November 18, 2017: Postgraduate Medical Journal
https://www.readbyqxmd.com/read/29147850/the-tear-cytokine-profile-in-patients-with-active-graves-orbitopathy
#11
Morgan Yang, Yvonne Chung, Stephanie Lang, Nobuyo Yawata, Lay Leng Seah, Audrey Looi
PURPOSE: The primary aim of this study is to isolate cytokines specific for active Graves' orbitopathy (GO) in the tears of affected patients. The secondary aim is to identify other cytokines of interest and to look at the profile of their levels over time. METHODS: This is a prospective pilot study conducted at the Singapore National Eye Centre. A total of 10 patients with active GO and 10 patients from each of 3 control groups were recruited. The 3 control groups were the following: age-matched normal female patients, patients with GO who were clinically inactive and patients with bilateral viral conjunctivitis...
November 16, 2017: Endocrine
https://www.readbyqxmd.com/read/29142837/preoperative-management-in-patients-with-graves-disease
#12
REVIEW
Eliana Piantanida
Graves' disease is the most frequent cause of hyperthyroidism in iodine-sufficient geographical areas and is characterized by the presence in patients' serum of autoantibodies directed against the thyrotropin receptor (TRAb) that cause overproduction and release of thyroid hormones. Clinical presentation results from both hyperthyroidism and underlying autoimmunity. The diagnosis is based on characteristic clinical features and biochemical abnormalities. If serum thyrotropin (TSH) is low, serum free thyroxine (FT4) and free triiodothyronine (FT3) concentrations should be measured to distinguish between subclinical (with normal circulating thyroid hormones) and overt hyperthyroidism (with increased circulating thyroid hormones)...
October 2017: Gland Surgery
https://www.readbyqxmd.com/read/29127744/-endocrine-orbitopathy-the-present-view-of-a-clinical-endocrinologist
#13
Jan Jiskra
Graves orbitopathy (GO) occurs in 25-50 % cases of Graves disease. Only in 5 % of patients the eye threatening GO is present. About 5-10 % and 10 % cases are present in euthyroid and hypothyroid patients respectively. All patients with GO should be assessed for activity (clinical activity score - CAS) and severity of the disease. Basic preconditions of the treatment are maintenance of euthyroidism, an effort to stop smoking, and referring of patients with moderate to severe and sight threatening GO to specialized thyroid eye centers...
2017: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/29127443/astragaloside-iv-attenuates-orbital-inflammation-in-graves-orbitopathy-through-suppression-of-autophagy
#14
Hong Li, Yali Zhang, Jie Min, Long Gao, Ren Zhang, Yucheng Yang
INTRODUCTION: Graves' orbitopathy (GO) is an autoimmune inflammatory disorder affecting the orbit around the eye. Astragaloside IV (AS-VI) is the main active ingredient of the Chinese herbal medicine Huangqi (Radix Astragali Mongolici). AS-IV exhibits antioxidant and anti-inflammatory properties, and shows therapeutic potential in a number of ischemic and inflammatory diseases; however, its pharmaceutical activities in GO remain undefined. MATERIALS AND METHODS: In this study, we investigated the effects of AS-IV on interleukin (IL)-1β-induced orbital fibroblast inflammation in vitro and GO orbital inflammation and ocular histopathological changes in vivo, as well as the underlying mechanisms responsible for these effects...
November 10, 2017: Inflammation Research: Official Journal of the European Histamine Research Society ... [et Al.]
https://www.readbyqxmd.com/read/29125145/the-2017-doyne-lecture-the-orbit-as-a-window-to-systemic-disease
#15
REVIEW
A A McNab
A very large number of disorders affect the orbit, and many of these occur in the setting of systemic disease. This lecture covers selected aspects of orbital diseases with systemic associations in which the author has a particular clinical or research interest. Spontaneous orbital haemorrhage often occurs in the presence of bleeding diatheses. Thrombosis of orbital veins and ischaemic necrosis of orbital and ocular adnexal tissues occur with thrombophilic disorders, vasculitis, and certain bacterial and fungal infections...
November 10, 2017: Eye
https://www.readbyqxmd.com/read/29120123/the-value-of-multidetector-computed-tomography-of-orbits-in-globe-protrusion-in-comparison-to-hertel-exophthalmometry
#16
Igor Đorić, Miloš Žarković, Zoran Radojičić, Nikola Repac, Aleksandar Janićijević, Krešimir Rotim, Goran Tasić, Lukas Rasulić
The use of multidetector computed tomography (MDCT) is an integral part of contemporary diagnostics of Graves‘ orbitopathy. The aim of this study was to assess proptosis measurement by MDCT and to compare it to the current standard, Hertel exophthalmometry. A cross-sectional study was conducted at the Clinical Centre of Serbia and included 91 patients (19 male and 72 female) with verified Graves‘ orbitopathy. Globe protrusion measured by MDCT (globe protrusion, GPR) was correlated to Hertel measured protrusion (HR)...
March 2017: Acta Clinica Croatica
https://www.readbyqxmd.com/read/29101123/role-of-microrna-146a-in-regulation-of-fibrosis-in-orbital-fibroblasts-from-patients-with-graves-orbitopathy
#17
Sun Young Jang, Seong Jun Park, Min Kyung Chae, Joon H Lee, Eun Jig Lee, Jin Sook Yoon
AIM: To examine the role of microRNA-146a (miR-146a) in the regulation of fibrosis in an in vitro model of Graves' orbitopathy (GO). METHODS: Orbital fat/connective tissues were harvested from patients with GO and non-GO for primary orbital fibroblast cultures. The effects of transforming growth factor-β (TGF-β), a potent cytokine that promotes fibrosis, on miR-146a expression were analysed in GO and non-GO orbital fibroblasts using quantitative real-time PCR...
November 3, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/29096933/modified-lateral-orbital-wall-decompression-in-graves-orbitopathy-using-computer-assisted-planning
#18
S Spalthoff, P Jehn, R Zimmerer, M Rana, N-C Gellrich, J Dittmann
Graves' orbitopathy, a condition seen in the autoimmune syndrome Graves' disease, affects the fatty tissue and muscles inside the orbit. Graves' orbitopathy is associated with increasing exophthalmos and sometimes leads to compressive dysthyroid optic neuropathy, resulting in progressive vision loss. Dysthyroid compressive optic neuropathy, functional problems, and cosmetic problems are the main indications for surgical decompression of the orbit, especially if conservative treatment has not led to a reduction in symptoms...
October 30, 2017: International Journal of Oral and Maxillofacial Surgery
https://www.readbyqxmd.com/read/29092078/double-blind-placebo-controlled-randomized-trial-of-selenium-in-graves-hyperthyroidism
#19
George J Kahaly, Michaela Riedl, Jochem König, Tanja Diana, Lutz Schomburg
Context: Supplemental selenium (Se) may affect the clinical course of Graves disease (GD). Objective: Evaluate efficacy of add-on Se on medical treatment in GD. Design: Double-blind, placebo-controlled, randomized supplementation trial. Setting: Academic endocrine outpatient clinic. Patients: Seventy untreated hyperthyroid patients with GD. Intervention: Additionally to methimazole (MMI), patients received for 24 weeks either sodium selenite 300 µg/d po or placebo...
November 1, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29071239/does-graves-orbitopathy-ever-disappear-answers-to-an-old-question
#20
Elena Sabini, Marenza Leo, Barbara Mazzi, Roberto Rocchi, Francesco Latrofa, Marco Nardi, Paolo Vitti, Claudio Marcocci, Michele Marinò
OBJECTIVES: There is a general belief that Graves' orbitopathy (GO) is a "chronic" disease, namely that patients' eyes do not return to how they were before GO appeared. Here, we investigate this issue from both the patient's and the physician's point of view. STUDY DESIGN: We studied the disappearance of GO, regardless of treatment, in all consecutive patients with a GO history of at least 10 years who came for a follow-up visit over a period of 5 years. Patients underwent an ophthalmological examination and were asked to answer a questionnaire on self-perception related to GO...
September 2017: European Thyroid Journal
keyword
keyword
33773
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"